NCT00651261 arm group db13e9e958b988ddf94cea2d8341456d [clinicaltrials_resource:NCT00651261/arm-group/db13e9e958b988ddf94cea2d8341456d]
dexamethasone acetate [clinicaltrials_resource:16f6366dcc3df2ecddd901fe426a7bfa]midostaurin [clinicaltrials_resource:49dc5b70325e663371d838d09abb9675]cytarabine [clinicaltrials_resource:9bcf615afa19815c3fce8ff6e9c4d1f1]daunorubicin [clinicaltrials_resource:9c95fbc075d388ff1c298ef3a8465f92]clinicaltrials:NCT00651261
arm group [clinicaltrials_vocabulary:arm-group]
NCT00651261 arm group db13e9e958b988ddf94cea2d8341456d [clinicaltrials_resource:NCT00651261/arm-group/db13e9e958b988ddf94cea2d8341456d]
Bio2RDF identifier
NCT00651261/arm-group/db13e9e958b988ddf94cea2d8341456d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 13e9e958b988ddf94cea2d8341456d
description [clinicaltrials_vocabulary:description]
Patients will receive a standa ...... taurin for twelve (12) months.
identifier
clinicaltrials_resource:NCT00651261/arm-group/db13e9e958b988ddf94cea2d8341456d
title
NCT00651261 arm group db13e9e958b988ddf94cea2d8341456d
@en
type
label
NCT00651261 arm group db13e9e9 ...... 3e9e958b988ddf94cea2d8341456d]
@en